Clinical trial / 2008
Pre-prostatectomy lycopene supplementation increased plasma lycopene without toxicity, but hormonal and biomarker changes were not significant versus control.
Forty-five men with clinically localized prostate cancer were randomized to receive 15, 30, or 45 mg of lycopene or no supplement from biopsy to prostatectomy (approximately 30 days). Plasma lycopene increased in all treatment groups, with the greatest increase in the 45 mg arm compared to controls, without producing toxicity. Serum free testosterone decreased with 30 mg lycopene, and total estradiol increased significantly with 30 mg and 45 mg from baseline to post-treatment, with no significant increases in serum PSA or tissue Ki-67. However, these changes were not statistically significant compared to the control group for the study's sample size and duration.
- Study type
- Phase II randomized controlled trial
- Who was studied
- 45 men with clinically localized prostate cancer (42 completed)
- What was measured
- Safety, plasma lycopene, serum steroid hormones, PSA, and tissue Ki-67
THE PAPER
Results of a Randomized Clinical Trial of the Action of Several Doses of Lycopene in Localized Prostate Cancer: Administration Prior to Radical Prostatectomy.
Kumar NB, Besterman-Dahan K, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Krischer JP. Clin Med Urol, 2008.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.